OBJECTIVES: Cardiovascular diseases are the most frequent cause of morbidity and mortality in many countries. That explains why medications for the treatment of cardiovascular diseases are the most used group of drugs. The aim of this study was to analyze the consumption of ACE inhibitors in Serbia during 2009 and 2010 year from pharmacotherapeutic and pharmacoeconomic point of view. METHODS: The data about the use of ACE inhibitors were taken from the Agency for Drugs and Medical Devices of the Serbia. RESULTS: During both analyzed years significant part of consumption of  ACE inhibitors was taken by more expensive drugs in Serbia, as fosinopril, cilazapril and quinapril, though they have not been used in Norway at all during that period. During 2009 year, fosinopril as a very expensive drug took second, and during 2010 it took third place on the list of the total utilization of monocomponent ACE inhibitors in Serbia. If the consumption of fosinopril in Serbia was reduced to a minimum as in Norway, and if the patients were offered enalapril instead, the savings in Serbia in 2009 would have been around 7.800.000,00 € only from this product. CONCLUSIONS: In Serbia in 2009 and 2010 year, ACE inhibitors and their fixed combination with diuretics are the most frequently used drugs within the group of drugs which is used for cardiovascular diseases treatment. The amount and structure of the utilized ACE inhibitors in Serbia is different in a lot of ways from the amount and structure of the utilized ACE inhibitors in Norway. Pharmacoeconomic analyses also show that large financial resources would be saved if the structure of the utilized ACE inhibitors in Serbia were more similar to the one in Norway.